PriceTargets.com logo

Neurogene - NGNE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $80.29
  • Forecasted Upside: 191.42%
  • Number of Analysts: 8
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 2 Strong Buy Ratings
$27.55 As of 10/30/2026 05:00 PM ET
▼ -1.27 (-4.41%)

This chart shows the closing price for NGNE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Neurogene Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NGNE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NGNE

Analyst Price Target is $80.29
▲ +191.42% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Neurogene in the last 3 months. The average price target is $80.29, with a high forecast of $166.00 and a low forecast of $50.00. The average price target represents a 191.42% upside from the last price of $27.55.

This chart shows the closing price for NGNE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 investment analysts is to buy stock in Neurogene. This rating has held steady since August 2026, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/3/2026
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/4/2026
  • 2 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/2/2026
  • 2 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/1/2026
  • 2 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/31/2026

Latest Recommendations

  • 2 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/28/2026HC WainwrightReiterated RatingBuy ➝ Buy$65.00
10/15/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/8/2026JPMorgan Chase & Co.Initiated CoverageOverweight$60.00
9/23/2026William BlairUpgradeStrong-Buy
8/12/2026GuggenheimBoost TargetBuy ➝ Buy$69.00 ➝ $81.00
8/12/2026Canaccord Genuity GroupLower TargetBuy ➝ Buy$180.00 ➝ $166.00
8/12/2026HC WainwrightLower TargetBuy ➝ Buy$70.00 ➝ $65.00
7/17/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
6/9/2026HC WainwrightReiterated RatingBuy ➝ Buy$70.00
6/3/2026UBS GroupSet Target$70.00
6/3/2026Rodman & RenshawInitiated CoverageBuy$70.00
6/3/2026Rodman & RenshawUpgradeStrong-Buy$70.00
4/28/2026GuggenheimInitiated CoverageBuy$69.00
4/28/2026GuggenheimUpgradeStrong-Buy
4/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
4/6/2026Canaccord Genuity GroupLower TargetBuy ➝ Buy$180.00
2/27/2026Canaccord Genuity GroupInitiated CoverageBuy
1/26/2026Lifesci CapitalInitiated CoverageOutperform$50.00
1/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
1/13/2026HC WainwrightReiterated RatingBuy ➝ Buy$70.00
11/13/2025HC WainwrightBoost TargetBuy ➝ Buy$65.00 ➝ $70.00
10/31/2025HC WainwrightBoost TargetBuy ➝ Buy$45.00 ➝ $65.00
10/9/2025HC WainwrightReiterated RatingBuy ➝ Buy$45.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/2/2025HC WainwrightSet TargetBuy ➝ Buy$45.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
6/17/2025Craig HallumInitiated CoverageBuy$50.00
6/12/2025BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$22.00 ➝ $26.00
5/20/2025BMO Capital MarketsBoost TargetOutperform ➝ Outperform$16.00 ➝ $22.00
5/16/2025Robert W. BairdDowngradeStrong-Buy ➝ Hold$38.00 ➝ $24.00
5/13/2025HC WainwrightLower TargetBuy ➝ Buy$50.00 ➝ $45.00
4/14/2025BMO Capital MarketsLower TargetOutperform ➝ Outperform$45.00 ➝ $16.00
3/25/2025Robert W. BairdSet Target$38.00
3/25/2025William BlairReiterated RatingOutperform
3/25/2025HC WainwrightLower TargetBuy ➝ Buy$55.00 ➝ $50.00
11/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
11/20/2024BMO Capital MarketsLower TargetOutperform ➝ Outperform$60.00 ➝ $45.00
11/19/2024William BlairReiterated RatingOutperform
11/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
11/12/2024Stifel NicolausBoost TargetBuy ➝ Buy$44.00 ➝ $60.00
11/12/2024BMO Capital MarketsLower TargetOutperform ➝ Outperform$65.00 ➝ $60.00
11/12/2024Leerink PartnersBoost TargetOutperform ➝ Outperform$45.00 ➝ $72.00
11/12/2024HC WainwrightBoost TargetBuy ➝ Buy$49.00 ➝ $55.00
11/12/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$54.00 ➝ $72.00
8/12/2024HC WainwrightLower TargetBuy ➝ Buy$51.00 ➝ $49.00
6/27/2024BMO Capital MarketsInitiated CoverageOutperform$65.00
6/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$51.00 ➝ $51.00
6/11/2024Robert W. BairdUpgradeStrong-Buy
6/11/2024Robert W. BairdInitiated CoverageOutperform$54.00
6/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$51.00 ➝ $51.00
5/13/2024HC WainwrightLower TargetBuy ➝ Buy$55.00 ➝ $51.00
5/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$55.00
4/29/2024Leerink PartnersReiterated RatingOutperform
4/29/2024Leerink PartnersInitiated CoverageOutperform$46.00
3/21/2024William BlairInitiated CoverageOutperform$61.00
3/19/2024HC WainwrightBoost TargetBuy ➝ Buy$45.00 ➝ $55.00
3/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$45.00
1/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$45.00
1/8/2024HC WainwrightInitiated CoverageBuy$45.00
1/5/2024Stifel NicolausInitiated CoverageBuy$31.00
1/4/2024TD CowenInitiated CoverageOutperform
(Data available from 10/31/2021 forward)

News Sentiment Rating

0.43 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2026
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2026
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2026
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2026
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2026
  • 4 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2026

Current Sentiment

  • 4 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Neurogene logo
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.
Read More

Today's Range

Now: $27.55
Low: $26.77
High: $29.38

50 Day Range

MA: $30.73
Low: $21.56
High: $40.84

52 Week Range

Now: $27.55
Low: $15.93
High: $43.66

Volume

249,042 shs

Average Volume

363,653 shs

Market Capitalization

$551.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.7

Frequently Asked Questions

What sell-side analysts currently cover shares of Neurogene?

The following sell-side analysts have issued research reports on Neurogene in the last year: Canaccord Genuity Group Inc., Guggenheim, HC Wainwright, JPMorgan Chase & Co., Lifesci Capital, Rodman & Renshaw, UBS Group AG, Wall Street Zen, Weiss Ratings, and William Blair.
View the latest analyst ratings for NGNE.

What is the current price target for Neurogene?

0 Wall Street analysts have set twelve-month price targets for Neurogene in the last year. Their average twelve-month price target is $80.29, suggesting a possible upside of 191.4%. Canaccord Genuity Group Inc. has the highest price target set, predicting NGNE will reach $166.00 in the next twelve months. Lifesci Capital has the lowest price target set, forecasting a price of $50.00 for Neurogene in the next year.
View the latest price targets for NGNE.

What is the current consensus analyst rating for Neurogene?

Neurogene currently has 1 sell rating, 5 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NGNE will outperform the market and that investors should add to their positions of Neurogene.
View the latest ratings for NGNE.

What other companies compete with Neurogene?

Other companies that are similar to Neurogene include Vir Biotechnology, Palvella Therapeutics, Zenas BioPharma, Absci and Hemab Therapeutics. Learn More about companies similar to Neurogene.

How do I contact Neurogene's investor relations team?

Neurogene's physical mailing address is 535 W 24th Street, 5th Floor, New York, NY, 10011. The company's listed phone number is (877) 237-5020 and its investor relations email address is [email protected]. The official website for Neurogene is www.neurogene.com. Learn More about contacing Neurogene investor relations.